Biolex
（重定向自Epicyte）
Biolex Therapeutics was a biotechnology firm in the Research Triangle of North Carolina that was founded in 1997 and raised $190 million from investors. It filed for Chapter 7 bankruptcy on July 5, 2012.
The company focused on expression of difficult-to-synthesize recombinant proteins in its LEX platform, which used Lemna, a duckweed. The duckweeds are a family of small aquatic plants that can be grown in sterile culture. Biolex developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna. Therapeutic glycosylated proteins, including monoclonal antibodies and interferon (IFN-alpha2b) have been produced using the LEX platform.